An Open-label Multicenter Rollover Study to Provide Continued Treatment to Participants Previously Enrolled in a RVU120 Clinical Study
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Relapsed / Refractory Metastatic or Advanced Solid Tumors
Myelofibrosis
Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Acute Myeloid Leukemia with or without NPM1 Mutation
Спонсор: Ryvu Therapeutics S.A.
Налично на:
БГ
Обобщение
Trial status: Authorised
Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Описание
Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 29 participants
БГ
EN